Inventiva (NASDAQ:IVA) Shares Climb 7.8% – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shot up 7.8% during mid-day trading on Thursday. The stock traded as high as $3.13 and last traded at $3.0950. 717,502 shares changed hands during trading, a decline of 23% from the average daily volume of 926,099 shares. The stock had previously closed at $2.87.

Analyst Ratings Changes

A number of research analysts have weighed in on IVA shares. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Truist Financial boosted their target price on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Guggenheim upped their price target on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Cantor Fitzgerald started coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Finally, Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $15.86.

Inventiva Stock Performance

The business has a 50 day simple moving average of $4.04 and a 200 day simple moving average of $4.47.

Inventiva (NASDAQ:IVA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. Sell-side analysts predict that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Platt Investment Counsel LLC acquired a new position in Inventiva during the 3rd quarter worth approximately $45,000. Engineers Gate Manager LP raised its holdings in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva in the 1st quarter valued at $1,111,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.